Stock Events

Stock Events

Plus Therapeutics 

0
231
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15OctExpected
Q1 2026
Next
-0.9
-0.85
-0.79
-0.73
Expected EPS
-0.761808
Actual EPS
N/A

Financials

-450.91%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
4.51MRevenue
-20.35MNet Income

Analyst Ratings

43.25Average Price Target
The highest estimate is 43.25.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XMPN.STU. It's not an investment recommendation.
NVIDIA
28
NVDA
Amazon
27
AMZN
Microsoft
24
MSFT
Apple
22
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mustang Bio
MBIO
Mkt Cap4.07M
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focusing on cell and gene therapies for cancer, directly competing with Plus Therapeutics.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics AG is known for its gene-editing technology applied in cancer therapy, which competes with Plus Therapeutics' approach to cancer treatment.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders, competing with Plus Therapeutics' focus.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics, Inc. works on allogeneic CAR T therapies for cancer, a direct competitor to Plus Therapeutics' cancer treatment efforts.

About

Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
Show more...
CEO
Marc H. Hedrick
Employees
28
Country
United States
ISIN
US72941H4002
WKN
000A422GY

Listings

XNAS
US
CNSY
F
DE
XMP1.F
MU
DE
XMP1.MU
STU
DE
XMPN.STU

0 Comments

Share your thoughts

FAQ

What is Plus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Plus Therapeutics stocks are traded under the ticker XMPN.STU.
When is the next Plus Therapeutics earnings date?▼
Plus Therapeutics is going to release the next earnings report on October 15, 2026.
What were Plus Therapeutics earnings last quarter?▼
XMPN.STU earnings for the last quarter are -0.9 EUR per share, whereas the estimation was -0.73 EUR resulting in a -23.82% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Plus Therapeutics revenue for the last year?▼
Plus Therapeutics revenue for the last year amounts to 4.51M EUR.
What is Plus Therapeutics net income for the last year?▼
XMPN.STU net income for the last year is -20.35M EUR.
How many employees does Plus Therapeutics have?▼
As of September 06, 2026, the company has 28 employees.
In which sector is Plus Therapeutics located?▼
Plus Therapeutics operates in the Health & Wellness sector.
When did Plus Therapeutics complete a stock split?▼
The last stock split for Plus Therapeutics was on May 01, 2023 with a ratio of 1:15.
Where is Plus Therapeutics headquartered?▼
Plus Therapeutics is headquartered in HOUSTON, United States.